Roland Griffiths, Ph.D. on Psilocybin, Psychedelic Therapies & Mystical Experiences
Roland Griffiths discusses groundbreaking research on psilocybin's ability to produce sustained reductions in anxiety and depression in terminal cancer patients through 'mystical-type experiences' that reorganize personasummaryPsilocybin therapy for terminal cancer patients resulted in large, sustained decreases in anxiety and depression that lasted up to six months after a single treatment, with no significant relapse observed.takeawayPsilocybin's mechanism likely involves downstream glutamate-mediated effects similar to ketamine, potentially driving neurogenesis and neuroplasticity, though specific neural correlates of personality change are still betakeaway














